journal
MENU ▼
Read by QxMD icon Read
search

Leukemia & Lymphoma

journal
https://www.readbyqxmd.com/read/28937327/carfilzomib-dexamethasone-versus-subcutaneous-or-intravenous-bortezomib-in-relapsed-or-refractory-multiple-myeloma-secondary-analysis-of-the-phase-3-endeavor-study
#1
Hartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, Ruben Niesvizky, Wee-Joo Chng, Douglas Joshua, Katja Weisel, Andrew Spencer, Robert Z Orlowski, Shibao Feng, Karim S Iskander, Meletios A Dimopoulos
This is a secondary analysis of the phase 3 ENDEAVOR study comparing relapsed and/or refractory multiple myeloma (RRMM) patients receiving carfilzomib-dexamethasone (Kd) with those receiving subcutaneous (SC) bortezomib with dexamethasone (Vd) or intravenous (IV) Vd. Of Kd-treated patients, 356 Kd were pre-selected (by physician prior to randomization if to be randomized to Vd) for SC Vd (Kd [SC Vd]) and 108 for IV Vd (Kd [IV Vd], respectively. Of Vd-treated patients, 360 received SC Vd and 75 IV Vd. Kd (SC Vd) median PFS was not reached; SC Vd was 9...
September 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28937297/clinical-outcome-of-patients-with-early-stage-favorable-hodgkin-lymphoma-treated-with-abvd%C3%A2-%C3%A3-%C3%A2-two-cycles-followed-by-fdg-pet-ct-restaging-and-20%C3%A2-gy-of-involved-site-radiotherapy
#2
Sophia C Kamran, Heather A Jacene, Yu-Hui Chen, Peter M Mauch, Andrea K Ng
Our purpose was to assess outcome of patients with early-stage, favorable (per GHSG criteria) Hodgkin Lymphoma (HL) staged with FDG-PET/CT and treated with two cycles of adriamycin, bleomycin, vincristine, and dacarbazine (ABVD) followed by PET/CT assessment and involved-site radiotherapy (ISRT) to 20 Gy. Records of 23 patients who met eligibility criteria, treated between 2008 and 2016, were reviewed. PET response after two cycles of ABVD was independently assessed by a nuclear medicine physician. After two cycles of ABVD, 91...
September 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28933643/economic-burden-following-allogeneic-hematopoietic-stem-cell-transplant-in-patients-with-diffuse-large-b-cell-lymphoma
#3
Richard T Maziarz, Yanni Hao, Annie Guerin, Genevieve Gauthier, Marjolaine Gauthier-Loiselle, Simu K Thomas, Lamis Eldjerou
This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741)...
September 21, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28925785/risk-adjusted-therapy-in-chronic-lymphocytic-leukemia-a-phase-ii-cancer-trials-ireland-ctrial-ie-icorg-07-01-study-of-fludarabine-cyclophosphamide-and-rituximab-therapy-evaluating-response-adapted-abbreviated-frontline-therapy-with-fcr-in-non-del-17p-cll
#4
Niamh Appleby, David O'Brien, Fiona M Quinn, Liam Smyth, Johanna Kelly, Imelda Parker, Kathleen Scott, Mary R Cahill, Gerard Crotty, Helen Enright, Brian Hennessy, Andrew Hodgson, Maeve Leahy, Hilary O'Leary, Michael O'Dwyer, Amjad Hayat, Elisabeth A Vandenberghe
Minimal residual disease negative complete response (MRD-negative CR) provides an early marker for time to treatment failure (TTF) in CLL treated with fludarabine, cyclophosphamide, and rituximab (FCR). MRD was assessed after four FCR cycles (FCR4); MRD-negative CR patients discontinued treatment. Fifty-two patients (35M; 17F) were enrolled. Eighteen (18/52; 34.6%) patients reached MRD-negative CR after FCR4 and 29/52 (55.8%) were MRD-negative CR at end of treatment (EOT). Median TTF was 71.1 months (95% CI 61...
September 19, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28918710/trametinib-for-the-treatment-of-ighv4-34-map2k1-mutant-variant-hairy-cell-leukemia
#5
Leslie A Andritsos, Nicole R Grieselhuber, Mirela Anghelina, Kerry A Rogers, Sameek Roychowdhury, Julie W Reeser, Cynthia D Timmers, Aharon G Freud, James S Blachly, David M Lucas, Gerard Lozanski, Jeffrey A Jones, Katie Williams, Christopher Oakes, Dan Jones, Michael R Grever
No abstract text is available yet for this article.
September 18, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28918692/the-cyclin-dependent-kinase-4-6-inhibitor-abemaciclib-exerts-dose-dependent-cytostatic-and-cytocidal-effects-and-induces-autophagy-in-multiple-myeloma-cells
#6
Noriyoshi Iriyama, Hirotsugu Hino, Shota Moriya, Masaki Hiramoto, Yoshihiro Hatta, Masami Takei, Keisuke Miyazawa
The D-type cyclin (CCND)-cyclin-dependent kinase 4/6 (CDK4/6) complex has been implicated in multiple myeloma development. We investigated the biological activity of CDK4/6 inhibitor abemaciclib on cell growth and survival in three myeloma cell lines, KMS-12-PE, RPMI 8226, and IM-9. Abemaciclib inhibited myeloma cell growth in a dose-dependent manner in all cell lines, with significant differences seen at a concentration of 320 nM. Treatment with 1 μM abemaciclib increased the fraction of cells in the G0/G1 phase and decreased the fraction in the S-G2/M phases...
September 18, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28918689/chronic-lymphocytic-leukemia-is-becoming-more-complex-how-to-define-complex-karyotype
#7
Natalia Kreinitz, Aaron Polliack, Tamar Tadmor
No abstract text is available yet for this article.
September 18, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28918688/role-and-regulation-of-micrornas-targeting-btk-in-acute-myelogenous-leukemia
#8
Lara Rizzotto, Tzung-Huei Lai, Arianna Bottoni, Jennifer A Woyach, Rosa Lapalombella, Clara D Bloomfield, John C Byrd, Deepa Sampath
No abstract text is available yet for this article.
September 18, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28914567/chemotherapy-free-triple-combination-of-obinutuzumab-venetoclax-and-idasanutlin-antitumor-activity-in-xenograft-models-of-non-hodgkin-lymphoma
#9
Frank Herting, Thomas Friess, Pablo Umaña, Steven Middleton, Christian Klein
No abstract text is available yet for this article.
September 15, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28914556/acute-lymphoblastic-leukemia-during-the-third-trimester-of-pregnancy
#10
Anniek Vlijm-Kievit, Nori G E Jorna, Etelka Moll, Eva Pajkrt, Steven T Pals, Saskia Middeldorp, Bart J Biemond, Sacha S Zeerleder, Marieke A Tio, E Marleen Kemper, Mette D Hazenberg
No abstract text is available yet for this article.
September 15, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28914552/myelodysplastic-syndromes-mds-in-regular-care-in-germany-the-oldest-patients-come-to-the-fore
#11
Hans Tilman Steinmetz, Ulrich Germing, Annette Sauer, Bernd Lathan, Rüdiger Liersch, Hans Tesch, Jörg Heßling, Enno Moorahrend, Jens Uhlig, Marcel Reiser, Roja Wahdat, Norbert Gattermann, Uwe Totzke, Stephan Schmitz
No abstract text is available yet for this article.
September 15, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28914100/acute-myeloid-leukemia-and-the-infectious-diseases-consultant
#12
Victor Mulanovich, Dimitrios P Kontoyiannis
Infectious complications following treatment of acute myeloid leukemia (AML) are important causes of morbidity and mortality. The spectrum and complexity of these infections is reflected by the severe net state of immunosuppression of AML patients, that is dynamic and continuously changing, the polypharmacy, including the widespread use of anti-infectives and the complex epidemiology of severe and frequently resistant pathogens afflicting these patients. Infectious diseases (ID) consultants having a critical mass of expertise and intimate knowledge of the intricacies of leukemia care, add considerable value in improving outcomes of patients with AML who develop infections...
September 15, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28905668/the-impact-of-agent-orange-exposure-on-prognosis-and-management-in-patients-with-chronic-lymphocytic-leukemia-a-national-veteran-affairs-tumor-registry-study
#13
Craig Mescher, David Gilbertson, Nicole M Randall, Gobind Tarchand, Julie Tomaska, Lisa Baumann Kreuziger, Vicki A Morrison
Exposure to Agent Orange (AO) has been associated with the development of chronic lymphocytic leukemia (CLL). We performed a retrospective study of 2052 Vietnam veterans identified in the National VA Tumor Registry to assess the impact of AO exposure on CLL prognosis, treatment and survival. Prognostic factors did not differ based on exposure. Veterans exposed to AO were diagnosed younger (63.2 vs. 70.5 years, p < .0001) and had longer overall survival (median not reached vs. 91 months, p < .001)...
September 14, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28901817/treatment-and-prognosis-of-stage-i-follicular-lymphoma-in-the-modern-era-does-pet-matter
#14
Ohad S Bentur, Ronit Gurion, Anat Gafter-Gvili, Moshe Gatt, Lev Shvidel, Netanel A Horowitz, Ron Ram, Yair Herishanu, Nadav Sarid, Ora Paltiel, Chezi Ganzel, Natalia Kreiniz, Najib Dally, Odit Gutwein, Pia Raanani, Irit Avivi, Chava Perry
Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma. Patients with stage I disease are usually treated with radiotherapy (RT). In previous studies, mostly from the pre positron emission tomography-computed tomography (PET-CT) era, the 5 year progression-free survival (PFS) and overall survival (OS) rates of stage I disease were 60-80% and 80-93%, respectively. This study retrospectively evaluated the outcome of stage I FL which was treated with involved field RT in the PET-CT era between 2002 and 2015...
September 13, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28901815/high-grade-b-cell-lymphoma-of-the-peritoneum-as-a-result-of-transformation-of-a-cd5-negative-monoclonal-b-lymphocytosis-population-in-a-patient-with-myelodysplastic-syndrome-treated-with-5-azacytidine
#15
Maria Dimou, Maria Roumelioti, Aglaia Dimitrakopoulou, Catherin Bitsani, Sotiria Kotsanti, Panayiota Petsa, Paraskevi Papaioannou, Marie-Christine Kyrtsonis, Panayiotis Panayiotidis
No abstract text is available yet for this article.
September 13, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28901797/predictive-performance-of-early-warning-scores-in-acute-leukemia-patients-receiving-induction-chemotherapy
#16
John L Vaughn, David Kline, Nathan M Denlinger, Leslie A Andritsos, Matthew C Exline, Alison R Walker
No abstract text is available yet for this article.
September 13, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28901791/determinants-of-1-year-survival-in-critically-ill-acute-leukemia-patients-a-grrr-oh-study
#17
Márcio Tavares, Virginie Lemiale, Djamel Mokart, Frédéric Pène, Etienne Lengliné, Achille Kouatchet, Julien Mayaux, François Vincent, Martine Nyunga, Fabrice Bruneel, Antoine Rabbat, Christine Lebert, Pierre Perez, Anne-Pascale Meert, Dominique Benoit, Michael Darmon, Elie Azoulay
Acute leukemia (AL) is the most common hematological malignancy requiring intensive care unit (ICU) management. Data on long-term survival are limited. This is a post hoc analysis of the prospective multicenter data from France and Belgium: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique [A Research Group on Acute Respiratory Failure in Onco-Hematological Patients (French)] Study, to identify determinants of 1-year survival in critically ill AL patients. A total of 278 patients were admitted in the 17 participating ICUs...
September 13, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28901790/anti-cd123-chimeric-antigen-receptor-t-cells-cart-an-evolving-treatment-strategy-for-hematological-malignancies-and-a-potential-ace-in-the-hole-against-antigen-negative-relapse
#18
Katherine D Cummins, Saar Gill
Chimeric antigen receptor-modified T-cells (CART) are a potent and targeted immunotherapy which have induced remissions in some patients with chemotherapy refractory or relapsed (RR) hematologic malignancies. Hundreds of patients have now been treated worldwide with anti-CD19 CART cells, with complete response rates of up to 90%. CART therapy has a unique toxicity profile, and unfortunately not all responses are durable. Treatment failure occurs via two main routes - by loss of the CART cell population, or relapse with antigen loss...
September 13, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28901789/cardiac-side-effects-of-bruton-tyrosine-kinase-btk-inhibitors
#19
Chloe Pek Sang Tang, Julie McMullen, Constantine Tam
The development of bruton tyrosine kinase inhibitors (BTKi) has been a significant advancement in the treatment of chronic lymphocytic leukemia and related B-cell malignancies. As experience in using ibrutinib increased, the first drug to be licensed in its class, atrial fibrillation (AF) emerged as an important side effect. The intersection between BTKi therapy for B-cell malignancies and AF represents a complex area of management with scant evidence for guidance. Consideration needs to be taken regarding the interplay of increased bleeding risk versus thromboembolic complications of AF, drug interactions between ibrutinib and anticoagulants and antiarrhythmic agents, and the potential for other, as yet seldom reported cardiac side effects...
September 13, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28893133/rale051-a-novel-established-cell-line-of-sporadic-burkitt-lymphoma
#20
Alberto L'Abbate, Ilaria Iacobucci, Angelo Lonoce, Antonella Turchiano, Elisa Ficarra, Giulia Paciello, Federica Cattina, Anna Ferrari, Enrica Imbrogno, Claudio Agostinelli, Pierluigi Zinzani, Giovanni Martinelli, Enrico Derenzini, Clelia Tiziana Storlazzi
To date, the lack of chemo-naive cell models limited exploratory studies to define novel therapies for Burkitt lymphoma (BL). To obtain a useful tool for biological and translational studies for this tumor, we established the RALE051 cell line from the malignant ascitic fluid cells of a patient at initial diagnosis, not previously exposed to any treatment. The cell line was characterized by karyotyping, fluorescence in situ hybridization (FISH), single nucleotide polymorphism (SNP) array, immunohistochemistry, and RNA-Seq, revealing the persistence of biological and molecular features observed in the primary ascitic fluid, such as the cell morphology and immunophenotype, the occurrence of a t(8;22) translocation deregulating MYC, knock-out ID3 mutations in a compound homozygous state, and a mutated TP53...
September 11, 2017: Leukemia & Lymphoma
journal
journal
30440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"